### (19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 28 March 2002 (28.03.2002)

(10) International Publication Number WO 2002/024216 A3

- (51) International Patent Classification<sup>7</sup>: A61K 45/00, 38/17, 38/30, A61P 35/00 // A61K 45:00, 38:17
- (21) International Application Number:

PCT/US2001/029188

(22) International Filing Date:

18 September 2001 (18.09.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/233,840

19 September 2000 (19.09.2000)

- (71) Applicant (for all designated States except US): BIOEX-PERTISE, LLC [US/US]; 525 Del Rey Avenue, Suite B, Sunnyvale, CA 94085 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): MASCARENHAS, Desmond [US/US]; 27233 Sherlock Road, Los Altos Hills, CA 94022 (US).
- (74) Agents: BUFFINGER, Nicholas, S. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 15 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR USE OF IGF-BINDING PROTEIN FOR SELECTIVE SENSITIZATION OF TARGET CELLS IN

(57) Abstract: New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

International Application No Per/US 01/29188

Relevant to claim No.

1-22

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K45/00 A61K38/17 //A61K45:00,38:17

C. DOCUMENTS CONSIDERED TO BE RELEVANT

A61K38/30

A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Category °

χ.

Minimum documentation searched (classification system followed by classification symbols) IPC 7-A61K-A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data, PAJ, CHEM ABS Data

Citation of document, with indication, where appropriate, of the relevant passages

24 November 1998 (1998-11-24)

US 5 840 673 A (SEIZINGER BERND R ET AL)

|  | column 2, line 9 - line 24<br>column 4, line 32 - line 58<br>claims 1-4  |   |             |  |
|--|--|---|-------------|--|
| X  | FOWLER C A ET AL: "IGFBP-3 and opposing actions on paclitaxel in apoptosis of human breast cancer Hs578T."  GROWTH HORMONE AND IGF RESEARCH, vol. 9, no. 5, October 1999 (199 page 368, XP009005668  5th International Symposium on Insulin-Like Growth Factors; Brig England, UK; October 31-November ISSN: 1096-6374 the whole document  | nduced<br>cells,<br>9-10),  | 1-22        |  |
| X Furt   | her documents are listed in the continuation of box C.   | X Patent family members are listed  | in annex.   |  |
| "A" docum<br>consid<br>"E" earlier<br>filing of<br>"L" docume<br>which<br>citatio<br>"O" docume<br>other   | ategories of cited documents:  ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another or or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "8" document member of the same patent family |             |  |
| Date of the actual completion of the international search  Date of mailing of the international search report  |  |   | arch report |  |
| 7 June 2004  |  | 1 1 06. 2004  |             |  |
| Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016 |  | Authorized officer Fayos, C   |             |  |

Interational Application No
PCT/US 01/29188

| C.(Continu | ation) DOCUMENTS CONSIDERED TO BE RELEVANT   | PCT/US 01/29188       |
|------------|--|-----------------------|
| Category ° |  | Relevant to claim No: |
| X          | PORTERA C A JR ET AL: "Targeting the insulin-like growth factor axis in the therapy of colorectal carcinoma liver metastasis."  GROWTH HORMONE & IGF RESEARCH: OFFICIAL JOURNAL OF THE GROWTH HORMONE RESEARCH SOCIETY AND THE INTERNATIONAL IGF RESEARCH SOCIETY. SCOTLAND APR 2000, vol. 10 Suppl A, April 2000 (2000-04), pages S47-S48, XP009005667 ISSN: 1096-6374 cited in the application column 2, paragraph 2 | 1-22                  |
| Х          | US 6 015 786 A (MASCARENHAS DESMOND ET AL) 18 January 2000 (2000-01-18) column 4, line 49 - line 57 column 11, line 66 - column 12, line 5   | 1,3,21,<br>22         |
| Х          | US 5 407 913 A (SOMMER ANDREAS ET AL)<br>18 April 1995 (1995-04-18)<br>claims 1,2,8  | 1,3,<br>20-22         |
| X          | US 5 527 776 A (MAACK CHRISTOPHER A ET AL) 18 June 1996 (1996-06-18) column 4, line 52 - column 5, line 13 column 6, line 58 - line 62 column 9, line 43   | 1,3,<br>20-22         |
| X          | US 6 017 885 A (ROSEN DAVID M ET AL) 25 January 2000 (2000-01-25) column 7, line 54 - column 8, line 7 column 9, line 44   | 1-3,6,<br>21,22       |
| Υ          | RAJAH ROOPMATHY ET AL: "IGFBP-3 mediates TNF-alpha induced apoptosis in the prostate cancer cell line, PC-3: Role of bcl-2 phosphorylation." PROSTATE, vol. 38, no. 4, March 1999 (1999-03), pages 352-353, XP009005670 International Symposium on Biology of Prostate Growth; Bethesda, Maryland, USA; March 15-18, 1998 ISSN: 0270-4137 the whole document   | 1-22                  |
|            |  |                       |

International Application No PC1/US 01/29188

|            |  | PC1/05 0. | 1/20100               |
|------------|--|-----------|-----------------------|
|            | ation) DOCUMENTS CONSIDERED TO BE RELEVANT   |           |                       |
| Category ° | Citation of document, with indication, where appropriate, of the relevant passages   |           | Relevant to claim No. |
| A          | BUCKBINDER L ET AL: "INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN 3 BY P53"  NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 377, no. 6550, 19 October 1995 (1995-10-19), pages 646-649, XP002025927 ISSN: 0028-0836 the whole document  |           |                       |
| P,X        | DE 199 51 824 A (FORSSMANN WOLF GEORG)<br>3 May 2001 (2001-05-03)<br>claims 1,24   |           | 1,3,21,<br>22         |
| Ρ,Υ        | FOWLER C A ET AL: "Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells."  INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 3, 2000, pages 448-453, XP002230887  ISSN: 0020-7136  page 449, column 2, paragraph 7  page 452, column 1, paragraph 2 - column 2 |           | 1-22                  |
| ,          |  |           |                       |
|            |  |           |                       |
|            |  |           |                       |
|            |  |           |                       |

rnational application No. PCT/US 01/29188

| Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)   |  |  |  |  |
|---|--|--|--|--|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:  |  |  |  |  |
| 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  |  |  |  |  |
| Although claims 1-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  |  |  |  |  |
| 2. X Claims Nos.: 1, 3, 4 (partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically: |  |  |  |  |
| see FURTHER INFORMATION sheet PCT/ISA/210   |  |  |  |  |
|   |  |  |  |  |
| Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).  |  |  |  |  |
| Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)   |  |  |  |  |
| This International Searching Authority found multiple inventions in this international application, as follows:   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| 1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.   |  |  |  |  |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  |  |  |  |  |
| of any additional fee.  |  |  |  |  |
| A such some of the required additional accraptions were timely paid by the applicant, this International Search Papert  |  |  |  |  |
| 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:                                 |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| Remark on Protest  The additional search fees were accompanied by the applicant's protest.  |  |  |  |  |
| No protest accompanied the payment of additional search fees.   |  |  |  |  |
|   |  |  |  |  |

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 3, 4 (partially)

Present claims 1, 3, 4 relate to an extremely large number of possible "co-administered agents or treatment regimens" which are to be combined with IGFBP-3. In fact, the claims contain so many possibilities that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely the chemotherapeutic agents of claim 2, and in particular those of claim 6.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

Interponal Application No PCT/US 01/29188

| Patent document cited in search report | Publication<br>date | Patent family Publication member(s) date  |
|--|---------------------|---|
| US 5840673 A                           | 24-11-1998          | AU 718451 B2 13-04-2000<br>AU 6975296 A 01-04-1997<br>EP 0871475 A2 21-10-1998<br>JP 2000502322 T 29-02-2000<br>NO 981127 A 13-03-1998<br>WO 9709998 A2 20-03-1997  |
| US 6015786 A                           | 18-01-2000          | US 6025368 A 15-02-2000 AU 738372 B2 13-09-2001 AU 6668598 A 09-09-1998 EP 0975358 A2 02-02-2000 JP 2001513085 T 28-08-2001 US 6025332 A 15-02-2000 WO 9836764 A2 27-08-1998 US 6514937 B1 04-02-2003 US 6518238 B1 11-02-2003                              |
| US 5407913 A                           | 18-04-1995          | AT 215835 T 15-04-2002  CA 2142455 A1 03-03-1994  E 69331802 D1 16-05-2002  E 69331802 T2 07-11-2002  C 661990 T3 17-06-2002  EP 0661990 A1 12-07-1995  ES 2174852 T3 16-11-2002  JP 8500827 T 30-01-1996  PT 661990 T 30-09-2002  WO 9404030 A1 03-03-1994 |
| US 5527776 A                           | 18-06-1996          | AT 226958 T 15-11-2002<br>AU 688793 B2 19-03-1998<br>AU 7731494 A 10-04-1995<br>DE 69431631 D1 05-12-2002<br>DE 69431631 T2 31-07-2003<br>EP 1238674 A2 11-09-2002<br>EP 0726911 A1 21-08-1996<br>JP 9507832 T 12-08-1997<br>WO 9508567 A1 30-03-1995       |
| US 6017885 A                           | 25-01-2000          | AU 713275 B2 25-11-1999<br>AU 3099995 A 16-02-1996<br>CA 2195474 A1 01-02-1996<br>EP 0800530 A1 15-10-1997<br>JP 10512235 T 24-11-1998<br>WO 9602565 A1 01-02-1996  |
| DE 19951824 A                          | 03-05-2001          | DE 19951824 A1 03-05-2001   |
|  |                     |   |